Neos Therapeutics at the JMP Securities Life Sciences Conference (Replay)
06/21/18 at 1:00 p.m. ET
Corporate ProfileNeos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have three approved ADHD products, two of which use our ODT technology and one of which is an extended-release (ER) oral suspension. Our growing ADHD product portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with ADHD.
- 05/31/18Neos Therapeutics to Participate in Two June Conferences
- 05/15/18Neos Therapeutics to Present at the UBS Global Healthcare Conference
- 05/09/18Neos Therapeutics Reports First Quarter 2018 Financial Results
- 05/02/18Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018